CA2017781A1 - Method of treatment of ischemia in brain - Google Patents

Method of treatment of ischemia in brain

Info

Publication number
CA2017781A1
CA2017781A1 CA002017781A CA2017781A CA2017781A1 CA 2017781 A1 CA2017781 A1 CA 2017781A1 CA 002017781 A CA002017781 A CA 002017781A CA 2017781 A CA2017781 A CA 2017781A CA 2017781 A1 CA2017781 A1 CA 2017781A1
Authority
CA
Canada
Prior art keywords
disorder
ischemia
bmy
brain
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002017781A
Other languages
English (en)
French (fr)
Inventor
Christopher G. Boissard
Duncan P. Taylor
Michael S. Eison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2017781A1 publication Critical patent/CA2017781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002017781A 1989-06-01 1990-05-29 Method of treatment of ischemia in brain Abandoned CA2017781A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US360,658 1989-06-01
US07/360,658 US5055470A (en) 1989-06-01 1989-06-01 Method of treatment of ischemia in brain

Publications (1)

Publication Number Publication Date
CA2017781A1 true CA2017781A1 (en) 1990-12-01

Family

ID=23418925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002017781A Abandoned CA2017781A1 (en) 1989-06-01 1990-05-29 Method of treatment of ischemia in brain

Country Status (8)

Country Link
US (1) US5055470A (ja)
EP (1) EP0410114A3 (ja)
JP (1) JPH0320222A (ja)
KR (1) KR910000151A (ja)
CA (1) CA2017781A1 (ja)
HU (1) HU205856B (ja)
IL (1) IL94525A0 (ja)
TW (1) TW198681B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
TW217382B (ja) * 1991-10-24 1993-12-11 Bristol Myers Squibb Co
DE4219973A1 (de) * 1992-06-19 1993-12-23 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
PT647137E (pt) * 1992-06-22 2008-11-24 Univ California Antagonistas dos receptores da glicina e a sua utilização
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US20050020483A1 (en) * 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
WO2009026282A2 (en) * 2007-08-21 2009-02-26 Midwestern University Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist
ES2614813T3 (es) 2009-04-30 2017-06-02 Midwestern University Nuevos tratamientos terapéuticos usando centaquina
EP3019242B1 (en) 2013-07-08 2020-08-19 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HU205856B (en) 1992-07-28
JPH0320222A (ja) 1991-01-29
EP0410114A2 (en) 1991-01-30
KR910000151A (ko) 1991-01-29
EP0410114A3 (en) 1992-01-02
IL94525A0 (en) 1991-03-10
TW198681B (ja) 1993-01-21
US5055470A (en) 1991-10-08
HU903291D0 (en) 1990-10-28
HUT54050A (en) 1991-01-28

Similar Documents

Publication Publication Date Title
US5055470A (en) Method of treatment of ischemia in brain
CA2687289C (en) A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
US4891380A (en) Novel treatment
PT838223E (pt) Inibidor do edema cerebral
EP0514023B1 (en) Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
US6897229B2 (en) Synergistic combination comprising roflumilast and a PDE-3 inhibitor
US4601897A (en) Prazosin-pirbuterol combination for bronchodilation
CA2152191C (en) Therapeutic agent for glaucoma and ocular hypotensive agent
EP0345948A2 (en) Use of 5-HT1A agonists for the manufacture of a medicament protecting against ischaemic damage
CA1267093A (en) Antiasthmatic
JPH10101566A (ja) 網膜保護剤
DE2721259A1 (de) Verwendung von benzamiden bei der bekaempfung der symptome, die mit asthma verbunden sind
JP2005206590A (ja) ナトリウムチャネルサイト２選択的阻害剤
US4159332A (en) Prevention of or reduction in severity of myocardial infarction
JPH09136830A (ja) 網膜保護剤
CA2133805A1 (en) Composition for prophylaxis and treatment of myopia
CA1209047A (en) Therapeutic composition containing piracetam analog
NZ532022A (en) Enhancement of learning and memory and treatment of amnesia
GB2189703A (en) Vinpocetine
CA2030421C (en) Agent for treatment of cerebrovascular contraction
AU688729B2 (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
KR19990054941A (ko) 유기인제 중독에 대한 복합예방제
JPH05262648A (ja) 脳障害改善剤
JPH02264719A (ja) 抗けいれん剤
CA2114267A1 (en) Use of oxidase inhibitor with dextromethorphan to treat intractable coughing and dermatitis

Legal Events

Date Code Title Description
FZDE Discontinued